Bayer AG (OTCMKTS:BAYRY) – Research analysts at Jefferies Group issued their FY2022 EPS estimates for Bayer in a research report issued on Tuesday. Jefferies Group analyst J. Holford forecasts that the company will post earnings per share of $2.94 for the year.
Other equities research analysts have also issued reports about the company. Zacks Investment Research lowered Bayer from a “buy” rating to a “hold” rating in a research report on Thursday. ValuEngine raised Bayer from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Finally, BNP Paribas raised Bayer from a “neutral” rating to an “outperform” rating in a research report on Monday, September 25th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Bayer has an average rating of “Hold” and an average target price of $36.00.
Bayer (OTCMKTS:BAYRY) last released its quarterly earnings results on Thursday, October 26th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.29 by $0.14. Bayer had a return on equity of 18.53% and a net margin of 10.88%.
TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/18/bayer-ag-bayry-to-post-fy2022-earnings-of-2-94-per-share-jefferies-group-forecasts.html.
Bayer Company Profile
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.